Drug Profile
NLS FMAU
Alternative Names: NLS-FMAU; NVLS/FMAULatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator University of Southern California
- Developer NuView Life Sciences
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Cancer(Diagnosis) in USA
- 20 Apr 2016 Chemical structure information added